Related Experiment Video
Updated: Jul 14, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Catatonia in neurodevelopmental disorders: assessing catatonic deterioration from baseline
Aaron J Hauptman1, David Cohen2, Dirk Dhossche3
1Neurobehavioral Unit, Department of Psychiatry, Kennedy Krieger Institute, Baltimore, MD, USA; Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Insights
Diagnosing and managing catatonia in individuals with autism spectrum disorder presents challenges. This study proposes a novel measure to assess catatonia, differentiating it from underlying neurodevelopmental disorders.
Area of Science:
- Neuropsychiatry
- Developmental Neuroscience
- Autism Spectrum Disorder Research
Background:
- Catatonia is a specifier for autism spectrum disorder (ASD) in the DSM-5.
- Clinical practice reveals diagnostic and management challenges for catatonia in patients with neurodevelopmental disorders, particularly ASD.
- Existing diagnostic and treatment paradigms require refinement for this population.
Purpose of the Study:
- To summarize current literature on catatonia in neurodevelopmental disorders, including ASD.
- To outline concerns regarding the diagnosis and management of catatonia in this patient group.
- To propose a novel conceptual framework and practical measure for diagnosing and monitoring catatonia in individuals with neurodevelopmental disorders.
Main Methods:
- Literature review on catatonia in neurodevelopmental disorders.
- Development of two novel concepts: 'personalized score at baseline' and 'catatonic deterioration from baseline'.
- Proposal for a comprehensive measure considering motor, medical, functional, and neurobehavioral symptoms.
Main Results:
- Current diagnostic and treatment approaches for catatonia in neurodevelopmental disorders are insufficient.
- A need exists for a specialized measure to differentiate catatonia from underlying neurodevelopmental conditions.
- The proposed concepts aim to provide a baseline estimate and assess deterioration due to catatonia.
Conclusions:
- A new measure is needed to accurately diagnose and monitor catatonia in individuals with neurodevelopmental disorders.
- The proposed 'personalized score at baseline' and 'catatonic deterioration from baseline' offer a novel approach.
- This framework aims to support clinicians and researchers working with this underserved population.
Abstract:
Despite the inclusion of catatonia as a specifier of autism spectrum disorder in DSM-5, we-a team of child and adolescent neuropsychiatrists who specialise in paediatric catatonia and neurodevelopmental disorders-have identified a number of issues with the diagnosis and clinical management of catatonia in our patients. In this Personal View, we summarise the literature regarding catatonia in people with neurodevelopmental disorders, including autism spectrum disorder, describe our concerns, and offer a novel approach to addressing important issues with current diagnostic and treatment paradigms. We emphasise the need for a measure to diagnose and monitor people with catatonia and their history of neurodevelopmental disorders. This measure should consider previous complex and underlying motor, medical, functional, and neurobehavioural symptoms. We propose two concepts for understanding catatonia that relate to the baseline status of an individual: the personalised score at baseline, an estimate of premorbid neurobehavioral and motor symptoms, and the catatonic deterioration from baseline, an estimate of current features that are due to catatonia rather than an underlying neurodevelopmental disorder. We hope this measure will provide a practical tool for clinicians and researchers working with this underserved and high-risk population.
More Related Videos
05:52Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Related Concept Videos
Alterations in Muscle Tone ll
Alterations in Muscle Tone lll